Top 50 Medical Startup Investors in Europe in September 2025

Investor	Medical Europe investments
Bpifrance	49
SOSV	33
Enterprise Ireland	27
Parkwalk Advisors	24
HTGF (High-Tech Gruenderfonds)	24
UK Innovation & Science Seed Fund	20
Deepbridge Capital	20
Scottish Enterprise	18
Sofinnova Partners	18
Oxford Science Enterprises	18
Kurma Partners	16
Novo Holdings	15
Oxford Technology Management	15
Idinvest Partners	14
Bayern Kapital	14
Scottish Investment Bank	14
Archangels	14
Oxford Science Enterprises	14
Mercia Fund Managers	13
Karista	13
GM&C Life Sciences Fund	13
Forbion Capital Partners	13
BioInnovation Institute	13
M Ventures	12
Speedinvest	12
Wellington Partners	12
Jonathan Milner	12
Almi Invest	12
Wellcome Trust	12
Northstar Ventures	11
Development Bank of Wales	11
Catapult Ventures	11
KfW	11
Cambridge Innovation Capital	11
Seventure Partners	10
MIG Capital	10
GO CAPITAL	10
Oxford Capital	10
Newable Private Investing	10
APEX Ventures	10
Chalmers Ventures AB	10
AlbionVC	10
Meusinvest (Noshaq)	9
Western Development Commission	9
Italian Angels for Growth	9
Seroba Life Sciences	9
AIB Seed Capital Fund	9
IP Group	9
Nesta Ventures	9
Nina Capital	9

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Investment focus

Software, Information Technology, Health Care
Seed, Funding Round, Series A
France, United States, Switzerland

Portfolio highlights

AUSTRAL Dx — AUSTRAL Dx is developing a new imaging technique based on airborne ultrasounds in order to map the vibrations coming from the lungs. The company was founded in 2021 and is based in Paris.
Aircap — Aircap revolutionizes investment with a banking platform dedicated to investors.
Electra — Electra is a platform that provides Charging stations Ultrafast for electric vehicles.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Seed, Funding Round, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Axe — Axe provides modern logistics solutions for businesses of all sizes. Streamline your logistics process with our innovative platform.
Assiduous — The AI-enabled platform to do the heavy-lifting for business owners seeking finance for their aspiring growth company.
Galway Biomedical — Galway Biomedical is your trusted Original Design Manufacturing (ODM) partner for biomaterial based medical devices & implant products.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Ceryx Medical — Ceryx Medical Ltd are the revolutionary business behind a unique bioelectronic technology that could change the way diseases such as heart failure are treated.
Enhanc3D Genomics — Enhanc3D Genomics is a spinout company from Babraham Institute.

High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

Mevaldi — Mevaldi is a biotechnology company. They investigate, select, and bring to market new technologies in the field of bio-based chemicals. They provide a revolutionary approach that integrates the large-scale biological conversion of sugars to low-cost mevalonolactone with a further cascade of thermo-catalytic conversions to various bio-monomers.
TrustNXT — TrustNXT is the trust authority for digital media, providing innovative software solutions to safeguard digital photos and videos from manipulation. Our technology verifies the origin, content, and metadata of digital media, while advanced forensic tools empower users to assess the trustworthiness of visual content. With a mission to protectauthenticity and foster safer digital environments, TrustNXT is committed to combating fraud and ensuring the integrity of digital media in today's digital world.
Pactos — Pactos streamlines and digitizes processes to enable large and medium-sized businesses to effectively and centrally procure and manage their contingent labor.

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Messium — Messium's technology makes use of proprietary machine learning models and hyperspectral satellite constellations.
Spaceflux — As satellites become increasingly vital, Spaceflux tackles the growing challenges of orbital congestion and debris that put them at risk. Thanks to our proprietary global network of optical sensors, we provide data-driven space situational awareness services from LEO to Cislunar.
Myosin Therapeutics — Myosin Therapeutics is a privately-held biopharmaceutical company developing novel medications targeting cellular motor proteins.

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

AI-Sight — AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.
upLYFT — upLYFT is working on the next generation of smart wearables to help with musculoskeletal issues related to aging. Also working with pro athletes to help sporting individuals train harder and break records.
Spotlight Pathology — Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers.

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Seed, Grant, Funding Round
United Kingdom, United States, Japan

Portfolio highlights

Swurf — The work surfing platform. Making it easy for venues to welcome a new community of remote workers.
Gigged.AI — Get AI-powered, real-time visibility over your tech team capabilities to power internal mobility. Fill skill gaps with ease using our on-demand talent network.
Bright Ascension — Bright Ascension offers mission ready software in space and on the ground. Our integrated software is perfect for any satellite mission.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
One Biosciences — One Biosciences unlocks routine analysis of tumor heterogeneity through AI-powered single-cell technologies, transforming precision medicine.
Galvanize Therapeutics — Galvanize Therapeutics is an energy-based medical device technology that provides therapeutic products and services to deliver healthcare solutions. The company aims to become the global leader in delivering medical technology innovations that drive biological processes to treat a range of diseases, starting with treating chronic bronchitissymptoms, cardiac arrhythmias, and solid tumors.It was formed by Apple Tree Partners in 2022.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series B
United Kingdom, United States, Finland

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Series A, Seed, Series B
France, Switzerland, Spain

Portfolio highlights

DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Mission Bio — We offer the only multi-omics single-cell technology solution that simultaneously detects SNV, CNV, and protein data from the same cell. Find out more.
Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.

Investment focus

Biotechnology, Health Care, Software
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

OxCan — Enabling curative cancer treatment through early detection
CryoLogyx — Assay Ready Cells - Discover CryoLogyx's advanced cryopreservation solutions, optimized for cell-based assays in drug discovery. Simply thaw with cell culture medium, and they are ready for use within 24 hours post-thaw.
Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Funding Round
France, United States, Spain

Portfolio highlights

Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
StarTower — StarTower is a resource company built specifically for fully decentralized physical infrastructure and shared interaction. Based on the exclusive RIP encryption technology, StarTower realizes the interactive sharing of multiple resources with zero loss on mobile devices, thereby providing efficient resource transmission for terminal facilities. Itprovides more efficient, secure and reliable solutions in the fields of Internet of Things, smart cities, industrial automation, healthcare, etc.
Stilla Technologies — Stilla Technologies is taking digital PCR to a whole new level with a unique 6-color target detection capability

Bayern Kapital (founded at the end of 1995) is a wholly owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank). Bayern Kapital’s objective is to finance research and development as well as the market launch of new products, product diversifications, and expansion of the market share.The requesting company has to be located inBavaria. Industries are e. g. IT/software, life sciences, new materials, micro-systems and environmental technologies.Bayern Kapital and its funds have invested in more than 250 companies and currently manages funds to the value of EUR 340 m. The five investing funds currently managed by Bayern Kapital are Seedfonds Bayern, Clusterfonds Start-Up!, Innovationsfonds, Innovationsfonds EFRE and Wachstumsfonds Bayern.

Investment focus

Software, Health Care, Information Technology
Seed, Series A, Funding Round
Germany, United States, Finland

Portfolio highlights

abaut — abaut is a SaaS provider for the construction and mining industry. The company’s goal is the digital replication of construction and mining progress and processes by combining a multitude of data sources, which are processed with the help of AI. Their software enables site managers to make better decisions, by providing site managers a holisticview over his site. Therefore, the risk of inefficiencies, process bottlenecks and cost & schedule overruns is reduced. The company was founded in 2017 and is headquartered in Munich, Germany.
Filics — A scalable transport solution for standardized load carriers with a minimum energy footprint
Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.

Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

CSignum — Revolutionising underwater communications with electromagnetic technology for seamless data integration between surface & submerged devices.
Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Hungary

Portfolio highlights

Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Warwick Acoustics — Warwick Acoustics believe in creating products that are designed from the ground up in order to deliver the best personal audio listening experience available to customers.
Melius Cyber — Melius Cyber continuously monitors an organization's IT network, testing security and protecting it from the latest threats.

Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.

Investment focus

Software, Biotechnology, Health Care
Seed, Series A, Series B
France, United States, Finland

Portfolio highlights

Deemea — Deemea is a collaborative AI platform that connects and provides services for the analysis of medical data for physicians. It uses its expertise in clinical research, data science, and software development to help healthcare professionals.
Sitowie — Sitowie develops SaaS technology and tools to understand the degradation of buildings.
Brightflow — Brightflow operates as a medical device startup.

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Italy, Germany

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
Eeden — Eeden engages in the manufacture and supply of textiles.
Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Investment focus

Biotechnology, Medical, Health Care
Convertible Note, Pre-Seed, Debt Financing
Denmark, Germany, Switzerland

Portfolio highlights

NorFalk — Explore NorFalk and its new generation surfactants. Discover our specializations and subscribe to our newsletter today.
ArcanaBio — ArcanaBio is developing realtime biosurveillance solutions that minimize workplace disruptions and support health & wellness
Fuse Vectors — Fuse Vectors is disrupting the manufacturing process in order to provide universal access to gene therapy.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Biolinq — Introducing a revolutionary platform for metabolic health.
ChEmpower — ChEmpower is an advanced materials company that develops chemically reactive, abrasive-free planarization pads to improve chip yields and sustainability in semiconductor manufacturing.
Corvic AI — Corvic AI is pioneering a new era of Data-Centric AI Cognitive Infrastructure by transforming raw enterprise data into AI-ready intelligence.

Speedinvest is one of Europe’s most active early-stage venture capital funds, with more than €1.2bn in AuM and offices in Berlin, London, Munich, Paris, and Vienna. Our dedicated sector-focused teams (Climate Tech & Industrial Tech, Deep Tech, Fintech, Health & Bio, Marketplaces & Consumer Tech, SaaS & Infra) are the first to fundEMEA's most innovative pre-Seed and Seed tech startups. Our in-house operational experts and global network of industry leaders support our portfolio companies with growth, people (HR), market expansion, and more throughout every stage of their journeys. Bitpanda, GoStudent, Wayflyer, Open, CoachHub, Schüttflix, TourRadar, Adverity, and TWAICE are among our portfolio of 400+ companies.

Investment focus

Software, FinTech, Financial Services
Seed, Series A, Pre-Seed
United Kingdom, Germany, Austria

Portfolio highlights

ARX Robotics — ARX is a defence technology company that specialises in developing autonomous unmanned systems and sensors for the European defence sector.
Due — Discover our global payment platform. Powered by open, decentralised and interoperable networks.
Tibo Energy — To make sure you operate within the limits of your contract we control your network. We avoid congestion in your energy network.

Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Germany, United States, United Kingdom

Portfolio highlights

Hilo — Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com.
HepaRegeniX — HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the University Hospital Tübingen, which identified mitogen-activated protein (MAP) kinase kinase 4 (MKK4) as a keyregulator of liver regeneration. Work by Professor Zender’s team showed that using small RNA molecules to suppress MKK4 gene expression restored the regenerative capacity of hepatocytes, even in severely diseased livers. Founded in 2015, HepaRegeniX is developing small-molecule MKK4 inhibitors to treat liver disorders, potentially including nonalcoholic steatohepatitis.
Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United Kingdom, United States, Spain

Portfolio highlights

Quibim — Leading radiomics company pioneering quantitative imaging biomarkers and medical applications in precision medicine.
52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
Exciting Instruments — We're on a mission to simplify single-molecule fluorescence spectroscopy and make it accessible to all. Find out more about our company, our products and what makes us different.

Almi Invest is Sweden’s most active early-stage venture capital firm, investing in scalable startups across Sustainability, Industry, Tech, and Life Science.We invest from pre-seed to Series A, always co-investing with independent private investors to accelerate innovation and long-term success. Our portfolio spans sustainable solutions,industrial innovation, deep tech, SaaS, and life science, supporting startups that drive economic and environmental progress.With €430 million under management and over 1,000 investments since 2009, we have backed leading companies like MIPS, Tobii, and Neo4j, with notable exits to Google, Apple, Microsoft, and Qlik.Beyond capital, we offer engaged ownership, providing strategic guidance, active board participation, and access to an extensive investor network.Almi Invest is part of the Almi Group and is funded by the European Regional Development Fund, Almi AB, and regional partners.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Pre-Seed
Sweden, United States, United Kingdom

Portfolio highlights

Embedl AB — Efficient Deep Learning by Deep Learning model optimization
Epigenica — Epigenica focuses on advancing epigenomics through its EpiFinder™ platform, a multiplexed ChIP-seq technology for high-throughput analysis of epigenetic marks. The company offers R&D services for the development of therapeutic molecules and diagnostic methods using epigenetics. Epigenica aims to improve scientists' ability to capture andextract insights from the epigenome, contributing to precision medicine and the discovery of new biomarkers.
Polar Light Technologies — Polar Light Technologies focuses on developing the next generation of Nano and micro LED technology.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Series C, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

RenBio — RenBio develops antibody-based therapeutic solutions for the treatment of cancer and inflammatory diseases. RenBio's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint and antibody factory.
Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
Cultivarium — We develop molecular, hardware and software tools to accelerate the adoption of microbes for beneficial biotechnologies.

Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.

Investment focus

Software, Health Care, E-Commerce
Seed, Funding Round, Series A
United Kingdom, United States, Indonesia

Portfolio highlights

Nanovery — Founded by scientists specialised in Nanotechnology, Medicinal Chemistry and Artificial Intelligence, we are on a mission to enable early detection of cancer through a rapid and affordable blood test Backed by academics at top universities, clinicians, industrial leaders, and Entrepreneur First.
AI Hay — AI Hay develops an AI-driven answer engine that allows users to access information through a question-and-answer format. The company combines hyperlocal, culturally nuanced knowledge discovery engines with social loops to enhance community validation and perspectives. It utilizes in-house specialized large-language models, retrieval-augmentedgeneration (RAG), and social features to build a knowledge discovery platform that serves the community.
Magnitude Biosciences — Magnitude Biosciences is a biotechnology firm combine experience in ageing research, the nematode C. elegans and automation.

Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Debt Financing
United Kingdom, Australia, United States

Portfolio highlights

nisien.ai — Nisien.ai uses industry-leading AI for the detection, defence and resolution of online harm, for better online safety and digital wellbeing.
Ceryx Medical — Ceryx Medical Ltd are the revolutionary business behind a unique bioelectronic technology that could change the way diseases such as heart failure are treated.
Lumin Solutions — Making care recording simpler, safer & child-focused for UK youth care providers. MyLifePlan helps you save time, ensure compliance & deliver outstanding care. Discover how!

The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.

Investment focus

Health Care, Biotechnology, Medical
Funding Round, Seed, Series A
United Kingdom, United States, Israel

Portfolio highlights

Path Robotics — We create manufacturing robots that autonomously scan, position, and weld your parts without the need for skilled welders or robot programmers.
Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
Anello Photonics — Anello Photonics is founded by pioneers in silicon photonics and inertial navigation. The patented Anello SiPhOG gyroscope offers an affordable mass-market sensor with true Optical Gyroscope performance. The company is headquartered in Silicon Valley and funded by leading venture capital firms.

KfW gives impetus to economic, social and ecological development worldwide. As a promotional bank under the ownership of the Federal Republic and the LÃ¤nder (federal states), it offers support to encourage sustainable improvement in economic, social, ecological living and business conditions, among others in the areas of small and medium-sizedenterprise, entrepreneurialship, environmental protection, housing, infrastructure, education finance, project and export finance, and development cooperation.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Series A, Series B
Germany, India, Kenya

Portfolio highlights

Vectoflow — Vectoflow is an innovative company developing fluid-dynamic metrology devices for fluid flow and dynamics measurement. It offers standardized and customized flow measurement technology that measures the static and total pressure, velocity, and angle of attack of a flow. These products are used in motorsport, aviation, turbine machine development,and research sectors.
Electrochaea — Electrochaea is commercializing a disruptive, scalable technology to convert electric power into methane, the principal component of natural gas. Using CO2 as a feedstock gas, power can be efficiently converted to renewable natural gas for power storage, for transportation fuels, or for transmission via a natural gas network. The company licensedtechnology from the University of Chicago and is led by the Nidus Partners, a St. Louis investment group specializing in renewable energy. Mich Hein, a Nidus Managing Partner, serves as CEO.Electrochaea has developed a commercially viable and disruptive solution for utility-scale energy storage, grid balancing, and carbon reuse. Their proprietary process converts low-cost and stranded electricity and carbon dioxide into pipeline-grade renewable gas for direct injection into the existing natural gas grid, a conversion process known as “power-to-gas”.
CryoTherapeutics — USING CRYOTHERAPY TO TREAT AND PREVENT HEART ATTACKS

As a team, we have a passion for science and its potential to drive change. Through our expertise and our position in one of the country's most powerful science and technology ecosystems, we're able to identify and support the most promising entrepreneurs in knowledge intensive businesses and help them achieve their vision.With our financial backing and expert guidance, we're excited to enable the pioneers in life sciences and deep tech to create world-leading companies whose unique ideas bring financial success and global impact.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United Kingdom, United States, Ireland

Portfolio highlights

Sortera Bio — Sortera Bio operates as a biotechnology company. Sortera is committed to providing revolutionary solutions in biologics discovery.
Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates

Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy

Investment focus

Biotechnology, Health Care, Software
Series A, Funding Round, Series B
France, United States, Germany

Portfolio highlights

ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
Reelevant — Only 1 out of 10 people interact with marketing messages. Content is the bottleneck of personalization, not data. Personalization doesn't work because data are used to create targeted campaigns. Data must be used to create content because content creates interactions and drive conversion.Why: create content for people, not for campaigns(visual is the key to emotions) How: on-demand, when the user request, at the opening/reading/exposure (Pull content vs Push marketing) What: end-to-end widgets solutions like Live content, Individualization, Content Automation, Optimization, etc.Our visual content platform accelerates revenue, creates content based on any data (behavioral, contextual, etc.) created on the fly at the moment of exposure (on any channel (email, web, push notifications, in-app messages, etc.). We take advantage of existing data sources, nothing to create, we supercharge your marketing stack. Our data-driven Content Engine translates data from any source into on-demand visual content in milliseconds for each people.We believe in a new way of thinking about messages by shifting the paradigm of push marketing to transform any data into on-demand visual content. One unique content is created for each people on the fly at the moment people decide to read them (pull content), instead of when marketers decide to create them (push marketing).People are not data points, people don't buy products, they buy emotions. On-demand visual content is the new game!
Seaweed Concept — Seaweed Concept is a marine biotechnology company, that focuses on the innovative utilization of seaweed to provide high-quality ingredients to various industrial sectors

MIG Capital is one of the leading German VC Investors. We invest in European Deep Tech and Life Sciences from early to late stage (Seed, Series A, and beyond). We use investments to shape a better tomorrow, today. Our team currently manages 17 MIG public venture capital funds regulated by BaFin, the German financial markets authority. These fundsoperate with more than EUR 1.2 billion capital committed by >60,000 private investors across Germany and Austria.Today, our portfolio consists of 30 companies.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Funding Round, Series B
Germany, France, Austria

Portfolio highlights

AMSilk — AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.
Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
ASTRA Therapeutics — Astra - Therapeutics

GO Capital is an independent management company and a major player in regional Seed and Venture Capital since 2003. With offices in Brittany, Pays de la Loire, Normandy, Centre-Val de Loire and the South of France, GO Capital contributes to the financing of responsible innovation in these regions. With a team of investors with complementarysectoral experience, we have a solid track-record in DeepTech. GO Capital has nearly 400 million euros under management, and mainly finances technology leaders in the digital and healthcare sectors and in the industry of the future.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Seed, Series A
France, Canada, Israel

Portfolio highlights

BiOceanOr — BiOceanOr harnessed the power of Marine Biology and AI to deliver bio-guided services that optimize fish welfare and fish growth, while supporting aquaculture sustainability standards
Moea — MOEA recrute ! Consultez toutes nos offres d'emploi (CDI, CDD) ainsi que toutes nos offres de stage et postulez en ligne.
Reelevant — Only 1 out of 10 people interact with marketing messages. Content is the bottleneck of personalization, not data. Personalization doesn't work because data are used to create targeted campaigns. Data must be used to create content because content creates interactions and drive conversion.Why: create content for people, not for campaigns(visual is the key to emotions) How: on-demand, when the user request, at the opening/reading/exposure (Pull content vs Push marketing) What: end-to-end widgets solutions like Live content, Individualization, Content Automation, Optimization, etc.Our visual content platform accelerates revenue, creates content based on any data (behavioral, contextual, etc.) created on the fly at the moment of exposure (on any channel (email, web, push notifications, in-app messages, etc.). We take advantage of existing data sources, nothing to create, we supercharge your marketing stack. Our data-driven Content Engine translates data from any source into on-demand visual content in milliseconds for each people.We believe in a new way of thinking about messages by shifting the paradigm of push marketing to transform any data into on-demand visual content. One unique content is created for each people on the fly at the moment people decide to read them (pull content), instead of when marketers decide to create them (push marketing).People are not data points, people don't buy products, they buy emotions. On-demand visual content is the new game!

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Investment focus

Software, Health Care, Biotechnology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Egregious — Egregious is an advanced research & intelligence lab established to defend humans from AI and provides narrative intelligence solutions across the public and private sectors to protect organisations and online users from malign influence using AI-driven data acquisition, insights, and engagement.
Arcube — We make sure all travellers, frequent and infrequent, make the most of travel loyalty programs, using our data-driven approach, airlines can understand their customers and provide hyper-personalised offerings to boost value and retention.Arcube uses a data-driven approach to make the most of airline loyalty programs for both frequent andinfrequent flyers. Our software allows airlines to understand their customers and provide hyper-personalised offerings to boost value and retention at no extra cost to the airline.
FinCrime Dynamics — Our mission is to help make the world’s financial system safer through rapid deployment of effective AI for financial crime analytics, enabled by enriched synthetic data that captures the dynamics of fraud and money laundering and loads them into tailor-made scenarios that explore diverse threats that financial organisations are exposed to.Thisgoal has taken us to the forefront of Synthetic Data and Fincrime Analytics, and we are proud to have in our team people that have helped shape the state-of-the-art of these fields.Keywords: Finacial services, AML, Synthetic Data, Fintech, Machine learning, Big data, Simulation, Fraud Analytics, Compliance

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology

APEX Ventures is an early-stage venture capital fund that invests in start-ups grounded in unique and protectable technology. They provide support and resources and aims to develop their start-ups in their respective field. Their initial focus areas include digital media, business intelligence, cybersecurity, fintech, and the future of work.

Investment focus

Artificial Intelligence, Health Care, Software
Seed, Series A, Pre-Seed
Germany, United Kingdom, Austria

Portfolio highlights

Quibim — Leading radiomics company pioneering quantitative imaging biomarkers and medical applications in precision medicine.
Robeaute — Redesigning the future of neurosurgery by creating the new standard device that will provide surgeons with seamless access to delicate areas of the brain parenchyma and with real-time data.
HyperHeat — HyperHeat is building a cutting-edge, all-electric heating solution designed to reach temperatures of up to 2,000°C. Using renewable electricity HyperHeat is providing an efficient alternative to fossil fuel combustion. With an efficiency rate of up to 98%, HyperHeat is ideal for retrofitting industrial processes, enabling significant CO2reductions across industries like steel, cement, and chemicals. The scalable technology offers a cost-efficient approach to decarbonizing thermal processes, with a potential to reduce global CO2 emissions by over 4.5 gigatons annually.

We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS

Investment focus

Software, Biotechnology, Information Technology
Pre-Seed, Seed, Funding Round
Sweden

Portfolio highlights

Embedl AB — Efficient Deep Learning by Deep Learning model optimization
Adsorbi — Adsorbi use cellulose from the Nordic forest to help air purification companies to capture gaseous air pollutants.
Swedish Algae Factory — Our algae materials replace harmful and less efficient chemicals in high-end organic personal care products and has the potential of increasing the efficiency of solar panels.

AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/

Investment focus

Software, Information Technology, Health Care
Series A, Funding Round, Seed
United Kingdom, United States, France

Portfolio highlights

Kohort — How many users will your mobile game acquire, and how much more will they pour into your virtual economy? Try Ramp to find out.
OpenTrade — OpenTrade providers web3 treasurers, institutions, and accredited investors access to on-chain structured financial products backed by investment grade RWAs.
Latent Technology — Latent Technology builds the next-generation animation technology for virtual worlds.

Noshaq offers financial services to help businesses develop.

Investment focus

Biotechnology, Health Care, Medical
Series A, Seed, Funding Round
Belgium, France, Germany

Portfolio highlights

TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
Veoware — More coverage, shorter revisit time. Increasing target collection frequency through modular next-gen actuator technology.
Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.

Supporting communities to grow, investing in businesses to scale and planning for the future of the western region.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Funding Round, Series A
Ireland, United States

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
Peroptyx — Peroptyx is a platform that provides managed solutions for machine learning. At Peroptyx, they have assembled and pre-screened a qualified network of data evaluators across the globe. They strategically match ideal evaluators with each product to ensure authentic experiences through consistency and appropriate real-world contexts.
CitySwift — CitySwift is a data-driven scheduling and planning technology for urban bus networks. It uses artificial intelligence and machine learning to predict journey times and passenger demand, making routes more efficient. Schedulers can create optimized timetables that take into account traffic, events, and hundreds of other external factors, ensuringon-time performance and increased passenger satisfaction.CitySwift was established in 2016 and is operating in Galway, Ireland.

IAG is an angel investor network that offers access to its affiliates to early-stage venture opportunities. Its members to date have deployed over 22 million Euros to support 41 startups in the series seed/series A stage in many verticals, among which: Medtech, SAAS, e-commerce, Fintech, and high tech at large. Every investment opportunityat IAG is vetted by a professional team together with expert members of the group. Once invested, the company receives the support of up to two Investment champions, who bring their expertise to the table and help them succeed.

Investment focus

Software, E-Commerce, Health Care
Seed, Angel, Series A
Italy, United States, United Kingdom

Portfolio highlights

ALKemist Bio — ALKemist Bio is a biotech startup developing next-generation T cell therapies that target ALK-positive cancers. By reprogramming the immune system, the company aims to overcome resistance and deliver more effective, lasting treatments for solid tumors.
Rubedo Life Sciences — Rubedo Life Sciences is the Premier Longevity Company. Rubedo discovers and develops medicines to keep you biologically young.
Restorative Neurotechnologies — Siamo un'azienda di dispositivi medicali certificati per la riabilitazione cognitiva ed il trattamento di disturbi cognitivi post ictus.

Seroba is a leading European life sciences venture capital firm focused on value creation through backing winning innovations in biotech and medtech.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Ireland, United States, United Kingdom

Portfolio highlights

Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.

The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012.The Fund has a total of â‚¬30m under managementwith AIB and Enterprise Ireland both committing â‚¬15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success.The Fund managers are empowered to make seed investments of up to approximately â‚¬500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies.The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise.Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of â‚¬250,000 from the fund within the city and county of Dublin.Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed â‚¬250,000.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Ireland, United States, Jersey

Portfolio highlights

NewsWhip — The only real-time media monitoring platform that predicts the stories and topics that will matter in the hours ahead.
Offr — Offr is the new way to buy and sell property, quickly and transparently.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Investment focus

Health Care, Biotechnology, Information Technology
Seed, Series A, Funding Round
United Kingdom, United States, Australia

Portfolio highlights

Lumai — Lumai delivers fully optical computing for a quicker, smarter and more sustainable world. Lumai power the revolution of fully optical computing by working at the nexus of photonics and machine learning.
Alimetry — Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.
Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster

We bring bold ideas to life to change the world for good.

Investment focus

Biotechnology, Medical Device, Medical
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Citymart — Citymart powers cities to deliver services that work. Following best practices developed with leading cities around the world, Citymart connects cities and revolutionizes the way cities frame needs, complete procurements, and improve service delivery. Over 100 cities in 35 countries have adopted Citymart tools and methods to-date.
Featurespace — Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countriesto prevent fraud and financial crime.ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.
Radio Physics Solutions — Radio Physics Solutions is a security and investigation company that specializes in the fields of real-time concealed threat detection, Up to 30m Distance, autonomous, and unobtrusive. It specializes in providing early warning of threats concealed under peoples’ clothes, and so reduce the number of casualties caused by terrorists and criminalsglobally at schools, train stations, airports, government and military installations, tourist attractions and entertainment venues.Radio Physics Solutions was founded in 2009 and headquartered in Cambridgeshire, United Kingdom.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

Investment focus

Health Care, Artificial Intelligence, Medical
Seed, Pre-Seed, Series A
United States, United Kingdom, Germany

Portfolio highlights

CryoCloud — CryoCloud Accelerate your protein structure determination - Bring your cryo-EM data analysis to the next level by using our cloud-based image analysis workflow.
EarlySight — EarlySight start-up company is founded in order to accelerate the development and to bring the technology to clinics.
Magentiq Eye Ltd — AI assisted colonoscopy by MAGENTIQ EYE set a new standard of , recognized by the gastroenterology community for its superior performance.